Core & Main Inc. (NYSE:CNM), a leader in advancing reliable infrastructure with local service, nationwide, today announced the launch of an underwritten secondary public offering of 15 million shares of its
Treatment with HT-004 significantly reduced lung inflammation after ovalalbumin (OVA) challenge in an asthma and allergy mouse model
NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc.